This study looks at how safe and tolerable a medicine called Pegcetacoplan (also known as Syfovre) is for patients with Geographic Atrophy (GA). GA is a condition that damages part of the eye called the macula, often due to Age-Related Macular Degeneration (AMD). This study is observational, which means doctors will watch and record what happens without changing the treatment.

Key Points:

• The study is for people aged 60 or older with GA in one or both eyes.
• If you join, your eye will be checked using special imaging techniques to see how the treatment is working.
• You cannot join if you've had other eye treatments recently or if you have other eye diseases like uveitis or glaucoma.

To join, you should have good vision (better than 20/200) and be able to give consent. You should not have had certain eye surgeries or treatments recently. If you have a history of allergies to the study medicine, you cannot participate. The study involves regular eye check-ups to ensure the safety and effectiveness of the treatment.